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These recommendations are for the use of Fellows, specialist 
physicians, clinical haematologists and medical oncologists with an 
interest in the treatment of haematological disorders.
1. Scope
This guideline was developed to address the diagnosis and 
management of chronic myeloid leukaemia (CML) in the South 
African setting, with particular reference to the prescribing of BCR-
ABL tyrosine kinase inhibitors (TKIs), and the management of their 
side-effects. Special focus is also given to the monitoring of response 
to treatments, given the constraints and shortage of skills in this area 
in South Africa. The guideline is endorsed by the South African 
Society of Haematology.
2. Methods
The development of these recommendations was based on local 
expert opinion, best clinical practice and available treatment 
options, together with review of the latest international 
recommendations and recent clinical data. The 2009 International 
European LeukemiaNet (ELN) and 2010 National Collaborative 
Cancer Network (NCCN) guidelines for the diagnosis, monitoring 
and management of CML, and the major clinical trials for the three 
TKIs that are registered in South Africa, imatinib, dasatinib and 
nilotinib, were considered.
3. Limitations of the recommendations
These recommendations do not represent all the possible methods of 
management applicable to all patients; do not exclude any other reasonable 
methods; and will not ensure successful treatment in every situation. The 
unique circumstances of each patient, disease stage, co-morbid conditions 
and treatments available should be taken into account by the responsible 
physician when deciding on any specific therapy.
4. Introduction and overview
Chronic myeloid leukaemia is a disease of the haematopoietic stem 
cell characterised by a chromosomal translocation between the long 
arms of chromosomes 9 and 22 which leads to formation of the 
so-called Philadelphia chromosome. This t(9;22) translocation results 
in the formation of the BCR-ABL fusion gene, which codes for a 
novel protein tyrosine kinase (TK) that is constitutively activated and 
therefore leads to increased proliferation of myeloid cells, decreased 
apoptosis and adhesion, and genetic instability of the leukaemic cells. 
This genetic instability forms the basis for resistance to treatment and 
progression of disease.
The incidence of CML is cited at 2/100 000/year with a slight male 
preponderance; however, local South African incidence or prevalence 
data are lacking. Since the widespread use of TKIs, the number of 
patients surviving worldwide has increased greatly, resulting in a 
progressively increasing prevalence of this disease.
5. Diagnosis of CML
Many patients are asymptomatic and are diagnosed incidentally 
on the basis of a raised white blood cell (WBC) count. Clinical 
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Introduction. Chronic myeloid leukaemia (CML) is a chronic 
myeloproliferative disorder characterised by a chromosomal 
translocation between the long arms of chromosomes 9 and 22 
resulting in the formation of the BCR-ABL fusion gene. The 
management of CML has undergone major changes over the past 
decade. Novel treatment approaches have had a dramatic impact 
on patient outcomes and survival. Nevertheless, these outcomes 
can only be achieved in the context of expert management, 
careful monitoring of disease response, appropriate management of 
adverse events and timeous adjustments to therapy when responses 
are not achieved within stated time frames.
Aim. With the advent of novel treatments providing molecular 
responses, both the monitoring and management of CML have 
become more complicated. The aim of these recommendations was 
to provide a pragmatic yet comprehensive roadmap to negotiate 
these complexities.
Methods. Recommendations were developed based on local 
expert opinion from both the academic and private medical care 
arenas after careful review of the relevant literature and taking 
into account the most widely used international guidelines. About 
five meetings were held at which these recommendations were 
discussed and debated in detail.
Results. A comprehensive set of recommendations was compiled 
with an emphasis on diagnosis, investigation, treatment and 
monitoring of disease. Careful attention was given to circumstances 
unique to South Africa, funding constraints, availability and access 
to laboratory resources, as well as the effects of concurrent HIV 
infection.
Conclusion. Most patients with CML can live a reasonably 
normal life if their disease is appropriately managed. These 
recommendations should be of value to all specialists involved in 
the treatment of haematological disorders.
S Afr Med J 2011;101:840-846.
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features include symptoms such as fatigue, malaise, weight loss, 
abdominal fullness and early satiety (due to splenomegaly), and 
rarely bleeding due to platelet dysfunction. Clinical findings may 
include hepatosplenomegaly, gouty arthritis, pallor, bone tenderness 
or features of hyperviscosity in patients with a high WBC count 
(e.g. headaches, visual and neurological disturbances, dyspnoea and 
angina). Patients should be carefully evaluated for extramedullary 
disease beyond the liver and spleen, which may have prognostic and 
staging implications (Table I). Clinical findings, especially spleen 
size, should be carefully documented for follow-up purposes and for 
calculation of the Sokal score, which is of prognostic value (online 
calculator available at www.roc.se/sokal.asp).
6. Disease phases
CML occurs in three different phases (chronic phase (CP), accelerated 
phase (AP), and a blastic phase (BP)). Most patients present in the CP. 
Classification is either by the European LeukaemiaNet (ELN) or the 
World Health Organization (WHO) criteria.
7. Laboratory investigations
Table II sets out the required laboratory tests for a newly diagnosed patient 
with CML. These are key to the correct staging of the patient, form the 
basis for further follow-up, and have direct bearing on prognosis. 
8. Treatment with tyrosine kinase 
inhibitors 
Before the introduction of the TKIs, the treatment of CML included 
hydroxyurea, interferon alpha (IFN-α), low-dose cytarabine and 
allogeneic haematopoietic stem cell transplantation. With the advent 
of imatinib, which specifically targeted the TK activity of the 
oncogenic proteins encoded by BCR-ABL, the management of CML 
changed dramatically. The following sections provide an overview of 
the available data supporting the use of TKIs in CML.
8.1 Imatinib
Imatinib is a selective inhibitor of the BCR-ABL TK. Imatinib induces 
a complete haematological response (CHR) in 80 - 90% of patients 
with newly diagnosed CP CML (CP-CML), a complete cytogenetic 
response (CCyR) in 70 - 80%, and a major molecular response 
(MMR), i.e. 3-log reduction of BCR-ABL: BCR or other control gene 
levels compared with a standardised pre-treatment level by real-time 
quantitative polymerase chain reaction (RQ-PCR), or RQ-PCR <0.05 
- 0.1%, in 40% of patients.2
The landmark IRIS (International Randomized Study of Interferon 
and STI571) trial results led to the recommendation of imatinib as 
first-line therapy for patients with CML.3 The IRIS trial was a phase III, 
Table I. Phases of chronic myeloid leukaemia
European LeukaemiaNet (ELN) criteria1 WHO criteria
Chronic phase (CP)
None of the criteria for AP or BP met
Acceleration phase (AP)
Blast cells in PB or BM 15 - 29% Blasts 10 - 19% of WBCs in PB and/or nucleated BM cells
Blast cells + promyelocytes in PB or BM >30%; with blast cells <30% Peripheral blood basophils ≥20%
Basophils in PB ≥20%
Persistent thrombocytopenia (platelets <100×109/l) unrelated to therapy
Persistent thrombocytopenia (<100×109/l) unrelated to therapy or 
persistent thrombocytosis (>1 000×109/l) unresponsive to therapy
Increase in spleen size and increase in WBC unresponsive to therapy
Cytogenetic evidence of clonal evolution
Blastic phase (BP)
Blast cells in PB or BM ≥30% Blasts ≥20% of peripheral blood white cells or nucleated bone marrow cells
Extramedullary involvement (excluding liver and spleen) Extramedullary blast proliferation
Large foci or clusters of blasts in the bone marrow biopsy specimen
Note: Clinical trials often use the ELN criteria while most diagnostic laboratories report the WHO criteria.
PB = peripheral blood; BM = bone marrow. 
Table II. Initial work-up
Baseline laboratory investigations
FBC + differential
Urea and electrolytes, liver enzymes, serum LDH, serum urate
Pregnancy test
BM aspirate and trephine biopsy for:
Morphology, including differential count to determine phase of 
disease
Assessment of fibrosis
Cytogenetic assessment on BM to determine:
•    % Philadelphia-positive cells (preferably 20 metaphases)
•    Presence of variant Philadelphia chromosome translocation
•    Presence of additional abnormalities, e.g. double Ph, 
isochromosome 17q, trisomy 8
FISH analysis optional:
•    Only done where conventional cytogenetics not available or fails
•    Or, to document a BCR-ABL positivity for variant 
translocation and masked Ph
Note: If BM material unavailable (e.g. due to marrow fibrosis), 
analysable metaphases may also be obtained from blood leukocytes
Real-time RQ-PCR on PB to establish:
•   A baseline level
•    The transcript type (1 - 2% have atypical BCR-ABL fusion 
products that are undetectable by standard RQ-PCR)
FBC = full blood count; LDH = lactate dehydrogenase; BM = bone marrow; FISH = 
fluorescence in situ hybridisation RQ-PCR = real-time quantitative polymerase chain 
reaction; PB = peripheral blood.
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multicentre, randomised, open-
label, crossover trial in which 1 
106 patients with newly diagnosed 
CML were randomised to receive 
initial therapy with either 400 
mg imatinib or IFN-α plus low-
dose cytarabine.3 Responses were 
significantly in favour of imatinib, 
with a CHR rate at 18 months 
of 97% versus 69%, a major 
cytogenetic response (MCyR) 
rate of 87% versus 34.7%, and a 
CCyR rate of 72.6% versus 14.5% 
in the imatinib and low-dose 
cytarabine plus interferon arms, 
respectively.3 These results were 
obtained despite 90% crossing over 
from the interferon plus low-dose 
cytarabine arm to the imatinib 
arm.3 After 8 years of follow-up of 
the IRIS trial, the estimated event-
free survival (EFS) and overall 
survival (OS) rates were 81% and 
85%, respectively.4 
About 10% of patients never 
achieve a CHR on imatinib by 3 
months and about 25% do not 
achieve a CCyR by 18 months, 
thus fulfilling the ELN 2009 
criteria of treatment failure.5,6 
Treatment failure usually 
results from the development of 
mutations in the TK domain of 
the BCR-ABL gene which affects 
the binding of imatinib to the 
adenosine triphosphate (ATP) 
binding site of the BCR-ABL 
protein. About 20% of patients 
who initially achieve a CHR 
or a cytogenetic response lose 
their responses over time with 
subsequent disease progression.3 
Intolerance to treatment 
and poor compliance are also 
reasons for treatment failure and 
discontinuation.7,8 To overcome 
the problem of resistance, 
novel TKIs have been studied, 
two of which are commercially 
available in South Africa, namely 
nilotinib and dasatinib. South 
African regulatory authorities 
have approved both these TKIs 
for treatment of patients with 
resistance or intolerance to 
imatinib.
8.2 Dasatinib
Dasatinib is an oral Src and Abl 
kinase inhibitor with a potent BCR-ABL inhibitory effect.9,10 Approval 
by the Food and Drug Administration (FDA) for the treatment of all 
phases of imatinib-resistant CML and Philadelphia (Ph)-positive 
acute lymphoblastic leukaemia (ALL) was granted in 2006. This was 
based on the efficacy and safety findings of the open-label phase 2 
START studies (Sarcoma (SRC)/ABL Tyrosine Kinase Inhibitions 
Activity Research Trials of Dasatinib) aimed at patients resistant or 
Fig. 1. Treatment of chronic myeloid leukaemia.
Fig. 2. Monitoring response to treatment in chronic myeloid leukaemia. Note: The recommended monitoring time-
frames are for responding patients only. Patients not fulfilling the various response criteria should be evaluated more 
frequently and offered alternative management.
GUIDELINE
842 November 2011, Vol. 101, No. 11  SAMJ
intolerant to imatinib.11-15 In the START-R study, high-dose imatinib 
(400 mg twice daily) was compared with dasatinib (70 mg twice daily) 
in 150 imatinib-resistant (to 400 - 600 mg daily) patients in CP CML.15 
Significantly higher response rates were seen with dasatinib when 
compared with high-dose imatinib at 24 months, with a CCyR rate 
of 44% versus 18% in the two groups, respectively.15 These responses 
were durable, with MCyR maintained in 90% of dasatinib responders 
compared with 74% of imatinib responders.15 Evidence from dose 
optimisation studies led to a change in the recommendations, with 
100 mg as a once-daily dose recommended for CML in CP and 140 
mg once daily for CML in advanced-phase CML (AP and BP) and 
Ph-positive ALL.16,17 The phase III dasatinib versus imatinib study in 
treatment-naïve CML patients (DASISION) compared the efficacy 
and safety of dasatinib (100 mg once daily) with imatinib (400 mg 
once daily) in patients with newly diagnosed CP CML and confirmed 
a CCyR at 12 months of 77% and 66% (p=0.007) with dasatinib and 
imatinib, respectively.18 The impact of these recent findings within 
the current registered indications, recommendations and current 
socio-demographic and socio-economic setting in South Africa is 
still under review. In South Africa, dasatinib remains registered for 
the treatment of CML, following intolerance or resistance to imatinib 
or other first-line therapies for CML and Ph-positive ALL.
8.3 Nilotinib
Nilotinib is also a second-generation TKI that inhibits the BCR-ABL 
TK more potently and selectively than imatinib.6,19,20 Nilotinib was 
approved by the FDA and the Medicines Control Council (MCC) 
for treating imatinib-intolerant and resistant patients with CML 
in CP and AP (but not for BP or Ph-positive ALL). In a phase II 
open-label study evaluating 280 CP-CML patients who had imatinib 
resistance or intolerance, MCyR and CCyR rates of 48% and 31%, 
respectively, were achieved.21 Responses were found to be durable 
Table III. Definitions of response
Haematological Complete (CHR) WBC <10×109/l
(check every 2 weeks until CHR, then 3-monthly) Basophils <5%
No myelocytes, promyelocytes, 




Cytogenetic Complete (CCyR) No Ph+ metaphases
(check every 6 months until CCyR, then every 1 - 2 years) Partial (PCyR) 1 - 35% Ph+ metaphases
Minor (mCyR) 36 - 65% Ph+ metaphases
Minimal (minCyR) 66 - 95% Ph+ metaphases
None (noCyR) >95% Ph+ metaphases
Molecular
(every 3 months once CCyR until MMR, then every 3 - 6 months)
Major (MMR) Ratio of BCR-ABL to ABL (or 
BCR or GUS) ≤0.1% on the 
international scale
Complete (CMR) Undetectable BCR-ABL 
mRNA transcripts by real-time 
quantitative and/or nested PCR in 
two consecutive blood samples of 
adequate quality (sensitivity >104)
Note: CHR, CCyR and MMR should be confirmed on 2 subsequent occasions. CCyr is evaluated by morphologic cytogenetics of at least 20 bone marrow metaphases. FISH of peripheral blood 
cells should be used only if marrow cells cannot be obtained. Molecular response by PCR is assessed on peripheral blood cells.
Table IV. South African modified ELN recommendations for goals of first-line therapy (imatinib) for CML
Optimal response Failure Warnings
Baseline N/A N/A Clonal chromosomal 
abnormalities (CCA)/Ph+
3 months CHR Less than CHR N/A
6 months At least PCyR (Ph+ ≤35%) No CyR (Ph+ >95%) N/A
12 months CCyR Less than PCyR (Ph+ >35%) Less than MMR
18 months MMR Less than CCyR Less than MMR





confirmed loss of MMR
*BCR-ABL mutations known to be poorly sensitive to imatinib.
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Table V. Managing common imatinib side-effects
Side-effect Mechanism Management
Non-haematological
Superficial oedema (peri-orbital) Inhibition of PDGFR in dermal dendrocytes
Occurs in >50% of pts
Related to dose, older age and females
Dose interruption seldom required
Limit salt intake
Topical phenylephrine 0.25%
Diuretics in severe cases, especially with severe 
peripheral oedema
Nausea and vomiting Local irritation gastric mucosa
Dose-related
Take imatinib with largest meal of day (2 hours 
before bedtime in pts with history of oesophagitis or 
hiatus hernia)
Anti-emetics if symptoms persist
If on higher dose (600 or 800 mg) – split dose in 
two
Muscle cramps Calcium and magnesium supplements
High fluid intake
Diarrhoea Inhibition of c-KIT in interstitial Cajal cells
Dose-related
Anti-diarrhoeals, e.g. loperamide
Take imatinib with large meal and water
Rash Inhibition of c-KIT in the skin Topical steroids effective in majority of cases
In severe cases, oral corticosteroids, dose 
interruptions or occasionally discontinuation may 
be required
Hepatic toxicity With grade 2 - 3 toxicities, dose interruption until 
toxicity is grade 1, followed by resumption of 
therapy at a reduced dose
Alternative therapies should be considered for 
grade 4 toxicity
Hypophosphataemia Multiple effects on bone turnover by inhibition 
of PDGFR
Phosphate replacement if severe
Haematological toxicity
Neutropenia Inhibition of c-KIT, which is essential for the 
development of normal blood cells
Suppression of the malignant clone until normal 
haematopoiesis replaces the marrow
Dose interruption is not recommended for grade 
1 - 2 toxicity
Grade 3 - 4 toxicity is defined as ANC <1×109/l: 
dose interruption until ANC 1 - 1.5×109/l, then 
resume at 400 mg/d if recovery within 2 weeks
In the event of recurrent grade 3 - 4 toxicity or 
delayed recovery, dose reduction to 300 mg
Consider growth factors for patients with recurrent or 
persistent grade 3 - 4 toxicity
Thrombocytopenia Inhibition of c-KIT, which is essential for the 
development of normal blood cells
Suppression of the malignant clone until normal 
haematopoiesis replaces the marrow
Dose interruption is not recommended for grade 
1 - 2 toxicity
Grade 3 - 4 toxicity is defined as a platelet count 
<50×109/l: dose interruption until platelet count 
is 50×109/l, then resume at 400 mg/d if recovery 
within 2 weeks
In the event of recurrent grade 3 - 4 toxicity or 
delayed recovery, dose reduction to 300 mg
Anaemia Inhibition of c-KIT, which is essential for the 
development of normal blood cells
Suppression of the malignant clone until normal 
haematopoiesis replaces the marrow
Dose interruption is not indicated for toxicity of 
any grade
Dose reductions may help in patients with chronic 
anaemia
Note: Toxicity grades according to CTCAE (Common Terminology Criteria for Adverse Events) criteria.
PDGFR = platelet-derived growth factor receptor.
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with long-term follow-up without the development of additional 
safety issues.22 Nilotinib was studied in first-line therapy in a phase III 
study, the Evaluating Nilotinib Efficacy and Safety in Clinical Trials 
– Newly Diagnosed Patients (ENESTnd) study, which compared the 
efficacy and safety of nilotinib (at a dose of either 300 mg or 400 
mg twice daily) with that of imatinib (400 mg per day) in patients 
with newly diagnosed CP-CML.23 The rates of CCyR by 12 months 
were significantly higher for nilotinib, namely 80% and 78% in the 
nilotinib 300 mg twice daily and 400 mg twice daily arms versus 65% 
in the imatinib 400 mg arm (p<0.001). A significant improvement in 
the time to progression to AP or blast crisis was seen in the nilotinib 
arms.23 In South Africa nilotinib is registered as second-line therapy 
for CML, following intolerance or resistance to imatinib.
9. Management of CML
This should be done by a trained clinical haematologist or oncologist 
with experience in the management of patients with CML. Fig. 1 
outlines the initial treatment of all three phases of CML.
9.1 Monitoring response in patients on imatinib
Monitoring of response to TKI therapy is very important (Fig. 2). 
Reaching specific goals within a given time has direct bearing on 
patient outcome. The aim is to get the patient to CCyR within 18 
months. Table III provides definitions of response and Table IV the 
criteria against which response is monitored. We believe that one of 
the most important ways of ensuring that a patient reaches CCyR 
is by monitoring and acting early when action is required. Failure 
to do so may jeopardise a patient’s chance of having a long-term 
response. On the basis of the degree of haematological response 
(HR), cytogenetic response (CyR), and molecular response (MR), 
and the time when these responses are achieved, the overall response 
to imatinib can be defined as optimal, suboptimal and failure.
9.2 Managing common side-effects of imatinib
Imatinib is generally well tolerated and has a favourable safety profile 
with an overall low incidence of severe adverse events in newly 
diagnosed CP-CML patients. The general management of common 
side-effects are outlined in Table V. 
10. Pregnancy and breastfeeding
For the management of patients who are pregnant, want to fall 
pregnant or are breastfeeding, see Table VI.
11. Human immunodeficiency virus 
(HIV) infection and CML
The occurrence of CML in association with HIV infection is likely to 
be coincidental rather than causal. Globally this association is rarely 
described.24 However, in South Africa, in the era of the HIV pandemic, 
it is being observed more frequently (M Patel, et al. – unpublished data).
CML in association with HIV presents with atypical and aggressive 
disease.24 Both CML and HIV may cause myelosuppression and 
immunosuppression. Despite this, both chemotherapy/TKIs and 
combination antiretrovirals (cARVs) have been used safely and 
effectively. cARVs should be commenced in all patients with HIV-
CML, irrespective of the CD4 count (as the CD4 count is usually 
elevated, mirroring the high white cell count and therefore not a 
reliable indicator of the stage of HIV in CML).
Drug interactions between cARVs and TKIs such as imatinib may 
require adjustment of treatment. Imatinib is mainly metabolised 
by the cytochrome P450 (CYP3A4) iso-enzyme, and concurrent 
administration of antiretroviral and antimicrobial drugs that induce 
or inhibit CYP3A4 may lead to drug-drug interactions.
In individuals who harbour both diseases, concurrent treatment 
with the TKIs (imatinib) and cARVs can result in appropriate control 
of the CML and HIV infection and long-term survival.
12. Role of allogeneic haematopoietic 
stem cell transplantation in CML
Since the introduction of imatinib in CP-CML, allogeneic stem cell 
transplantation is no longer considered as first-line treatment. Table 
VII lists indications for allogeneic stem cell transplantation.
13. Summary and conclusions
CML is a chronic myeloproliferative disorder characterised by a 
chromosomal translocation between the long arms of chromosomes 
9 and 12 resulting in the formation of the BCR-ABL fusion gene. 
This gene codes for a novel 210 kD TK leading to myeloid cell over-
proliferation, as well as genetic instability that forms the basis of 
resistance to treatment and progression to accelerated and blastic 
phases. The management of CML was revolutionised with the advent 
of imatinib, a small-molecule BCR-ABL TKI, approved in South 
Africa in 2002, which results in a MCyR in nearly 90% of patients and 
a CCyR in over 70%.3 After 7 years of follow-up of the landmark IRIS 
trial, CCyR has been maintained in 75% of patients with estimated 
EFS, OS and CML OS (the survival rate looking only at patients who 
died of CML) rates of 81%, 86% and 93%, respectively.
Unfortunately, up to 25% of patients fail to achieve a MMR by 18 
months, and a further 20% lose their responses, primarily owing to 
resistance to imatinib. Nilotinib, an imatinib analogue, and dasatinib, 
Table VI. Pregnancy and breastfeeding
Pregnancy Refer to specialised centres
Discuss with patient in detail
Multidisciplinary approach is required
Interferon-α has been used, although there are risks
Although the risk of fetal abnormalities is low 
with imatinib, avoidance of imatinib during 
conception and gestation is recommended
Effective contraception is recommended for men 
and women using TKIs
Breastfeeding Imatinib is secreted in the breastmilk
Owing to the potential for serious adverse events 
in the infant, breastfeeding is not recommended
Table VII. Indications for stem cell transplantation in 
advanced disease
1.    At diagnosis in AP or BP as first- or second-line therapy, 
preferably after imatinib 
2.   2nd or subsequent CP
3.   T315I mutation
4.    Imatinib failure in patient with good transplant risk score 
(EBMT risk score 0 - 2) and who is not a good candidate for a 
2nd-generation TKI
5.   All patients failing a 2nd-generation TKI
EBMT = European Group for Blood and Marrow Transplantation.
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an Src and Abl TKI, overcome imatinib resistance in most patients, 
except those with T315I mutations. Dasatinib has also been approved 
for patients in blast crisis. Nilotinib and dasatinib also show better 
molecular responses than imatinib in newly diagnosed patients, but this 
indication has not been approved in South Africa. Allogeneic stem cell 
transplantation plays a role in patients in subsequent CP after a blast 
crisis and with T315I mutations, although novel agents such as ponatinib 
may overcome resistance in these otherwise TKI-resistant patients.
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